Matthew W Kemp1, Masatoshi Saito2, Haruo Usuda3, Timothy J Molloy4, Yuichiro Miura2, Shinichi Sato3, Shimpei Watanabe3, Michael Clarke5, Michael Fossler6, Augusto Scmidt7, Suhas G Kallapur8, Boris W Kramer9, John P Newnham10, Alan H Jobe8. 1. School of Women's and Infants' Health, ARC Centre of Excellence, The University of Western Australia, Perth, Western Australia, Australia. Electronic address: matthew.kemp@uwa.edu.au. 2. School of Women's and Infants' Health, ARC Centre of Excellence, The University of Western Australia, Perth, Western Australia, Australia; Centre for Perinatal and Neonatal Medicine, Tohoku University Hospital, Sendai, Japan. 3. Centre for Perinatal and Neonatal Medicine, Tohoku University Hospital, Sendai, Japan. 4. Blood, Stem Cell, and Cancer Research Group, St Vincent's Centre for Applied Medical Research, Sydney, New South Wales, Australia. 5. Centre for Microscopy, Characterisation and Analysis, ARC Centre of Excellence, The University of Western Australia, Perth, Western Australia, Australia. 6. GlaxoSmith Kline, King of Prussia, PA. 7. Cincinnati Children's Hospital Medical Centre, Cincinnati, OH. 8. School of Women's and Infants' Health, ARC Centre of Excellence, The University of Western Australia, Perth, Western Australia, Australia; Cincinnati Children's Hospital Medical Centre, Cincinnati, OH. 9. School of Women's and Infants' Health, ARC Centre of Excellence, The University of Western Australia, Perth, Western Australia, Australia; Maastricht University Medical Centre, Maastricht, The Netherlands. 10. School of Women's and Infants' Health, ARC Centre of Excellence, The University of Western Australia, Perth, Western Australia, Australia.
Abstract
BACKGROUND: Antenatal steroids are standard of care for cases of anticipated preterm labor to improve neonatal outcomes. However, steroids are potent drugs, and their use in pregnancy remains largely unoptimized. OBJECTIVE: The objective of the study was to measure the maternofetal pharmacokinetics of constant, low-dose intravenous betamethasone phosphate infusions and correlate these data with the transcriptional effect exerted by subclinical betamethasone exposures on the ovine fetal lung. STUDY DESIGN: Thirty-two ewes carrying a single fetus had surgery to catheterize fetal and maternal jugular veins at 116 days of gestation (term, 150 days). Animals were recovered for 2 days and then were randomized to receive 2 sequential maternal intravenous infusions of either (n = 4/group) of the following: 1) saline, 0.125, 0.04, or 0.0125 mg/kg betamethasone phosphate over 3 hours; or 2) saline, 0.25, 0.08, or 0.025 mg/kg betamethasone phosphate over 12 hours. Each infusion was separated by 2 days. Fetal lung tissue was collected for analysis using quantitative polymerase chain reaction and an ovine-specific microarray. Plasma betamethasone levels from time-course catheter samples were determined by mass spectrometry. Data were assessed for distribution, variance, and tested by an analysis of variance. RESULTS: Betamethasone was detectable (>1 ng/mL) in fetal plasma only in animals randomized to 0.125 mg/kg 3 hour or 0.250 mg/kg 12 hour infusions. Fetal betamethasone half-lives were 1.7-2.8 times greater than maternal values. At maximum concentration, fetal plasma betamethasone levels were approximately 10% of maternal levels. Compared with saline control, all animals, other than those receiving 0.0125 mg/kg 3 hour betamethasone phosphate infusions, had evidence of dose-dependent glucocorticoid transcriptional responses in the fetal lung. CONCLUSION: Constant maternal betamethasone infusions delivering substantially lower fetal and maternal betamethasone maximal concentrations than those achieved with current clinical treatment protocols were associated with dose-dependent changes in glucocorticoid-response markers in the fetal lung. Further studies to determine the minimally efficacious dose of steroids for improving outcomes in preterm infants should be viewed as a priority. Copyright Â
BACKGROUND: Antenatal steroids are standard of care for cases of anticipated preterm labor to improve neonatal outcomes. However, steroids are potent drugs, and their use in pregnancy remains largely unoptimized. OBJECTIVE: The objective of the study was to measure the maternofetal pharmacokinetics of constant, low-dose intravenous betamethasone phosphate infusions and correlate these data with the transcriptional effect exerted by subclinical betamethasone exposures on the ovine fetal lung. STUDY DESIGN: Thirty-two ewes carrying a single fetus had surgery to catheterize fetal and maternal jugular veins at 116 days of gestation (term, 150 days). Animals were recovered for 2 days and then were randomized to receive 2 sequential maternal intravenous infusions of either (n = 4/group) of the following: 1) saline, 0.125, 0.04, or 0.0125 mg/kg betamethasone phosphate over 3 hours; or 2) saline, 0.25, 0.08, or 0.025 mg/kg betamethasone phosphate over 12 hours. Each infusion was separated by 2 days. Fetal lung tissue was collected for analysis using quantitative polymerase chain reaction and an ovine-specific microarray. Plasma betamethasone levels from time-course catheter samples were determined by mass spectrometry. Data were assessed for distribution, variance, and tested by an analysis of variance. RESULTS:Betamethasone was detectable (>1 ng/mL) in fetal plasma only in animals randomized to 0.125 mg/kg 3 hour or 0.250 mg/kg 12 hour infusions. Fetal betamethasone half-lives were 1.7-2.8 times greater than maternal values. At maximum concentration, fetal plasma betamethasone levels were approximately 10% of maternal levels. Compared with saline control, all animals, other than those receiving 0.0125 mg/kg 3 hour betamethasone phosphate infusions, had evidence of dose-dependent glucocorticoid transcriptional responses in the fetal lung. CONCLUSION: Constant maternal betamethasone infusions delivering substantially lower fetal and maternal betamethasone maximal concentrations than those achieved with current clinical treatment protocols were associated with dose-dependent changes in glucocorticoid-response markers in the fetal lung. Further studies to determine the minimally efficacious dose of steroids for improving outcomes in preterm infants should be viewed as a priority. Copyright Â
Authors: Tanzila Mahzabin; J Jane Pillow; Gavin J Pinniger; Anthony J Bakker; Peter B Noble; Robert B White; Kanakeswary Karisnan; Yong Song Journal: Pediatr Res Date: 2017-05-17 Impact factor: 3.756
Authors: T Brett Kothe; Emily Royse; Matthew W Kemp; Augusto Schmidt; Fabrizio Salomone; Masatoshi Saito; Haruo Usuda; Shimpei Watanabe; Gabrielle C Musk; Alan H Jobe; Noah H Hillman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-04-19 Impact factor: 5.464
Authors: Augusto F Schmidt; Matthew W Kemp; Judith Rittenschober-Böhm; Paranthaman S Kannan; Haruo Usuda; Masatoshi Saito; Lucy Furfaro; Shimpei Watanabe; Sarah Stock; Boris W Kramer; John P Newnham; Suhas G Kallapur; Alan H Jobe Journal: Am J Obstet Gynecol Date: 2017-11-11 Impact factor: 8.661
Authors: Liina Süvari; Otto M Helve; M Anneli Kari; L Ursula Turpeinen; P Anniina Palojärvi; Markus J Leskinen; Sture Andersson; A Cecilia Janér Journal: Pediatr Res Date: 2020-07-14 Impact factor: 3.756
Authors: Augusto F Schmidt; Paranthaman S Kannan; James P Bridges; Alyssa Filuta; Dakota Lipps; Matthew Kemp; Lisa A Miller; Suhas G Kallapur; Yan Xu; Jeffrey A Whitsett; Alan H Jobe Journal: Sci Rep Date: 2019-06-21 Impact factor: 4.379
Authors: Augusto F Schmidt; Matthew W Kemp; Mark Milad; Lisa A Miller; James P Bridges; Michael W Clarke; Paranthaman S Kannan; Alan H Jobe Journal: PLoS One Date: 2019-09-19 Impact factor: 3.240
Authors: Augusto F Schmidt; Alan H Jobe; Paranthaman S Kannan; James P Bridges; John P Newnham; Masatoshi Saito; Haruo Usuda; Yusaku Kumagai; Erin L Fee; Michael Clarke; Matthew W Kemp Journal: Pediatr Res Date: 2019-07-31 Impact factor: 3.756